HLS Therapeutics Inc. HLS Therapeutics Inc.

HLS Therapeutics Inc.

HLS

Rank in Stocks #20386
HLS Therapeutics Inc. operates as a specialized pharmaceutical firm,... HLS Therapeutics Inc. operates as a specialized pharmaceutical firm, concentrating on the acquisition and commercialization of medicinal products, primarily within the niche central nervous system (CNS) and cardiovascular (CV) sectors. Its reach extends across Canada, the United States, and international markets. The company's core product lineup includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsule formulation; and PERSERIS, an injectable risperidone product for treating schizophrenia. Additionally, HLS offers MyCare psychiatry laboratory assays and MyCare Insite tests for point-of-care therapeutic drug-level monitoring. Furthermore, the company possesses U.S. marketing privileges for Absorica, a commercial-stage dermatology solution, and Canadian rights for Trinomia, a cardiovascular therapeutic. It also manages a portfolio of royalty interests from four distinct healthcare products. Founded in 2018, HLS Therapeutics Inc. is based in Etobicoke, Canada.
Share Price
$2.63
Last synced: 2026-11-18
Market Cap
$81.18M
Change (1 day)
-0.57%
Change (1 year)
-25.86%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
EPS for HLS Therapeutics Inc. (HLS)
EPS as of September 2026 TTM: $-0.22
According to HLS Therapeutics Inc.'s latest financial reports, its current EPS (TTM) is $-0.22. At the end of 2025 the company had an EPS of $-0.40, an increase over its 2024 EPS of $-0.62.
EPS history for HLS Therapeutics Inc. from 2000 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $-0.22 -45.00%
2025 $-0.40 -35.48%
2024 $-0.62 -27.06%
2023 $-0.85 16.44%
2022 $-0.73 78.05%
2021 $-0.41 -14.58%
2020 $-0.48 -28.36%
2019 $-0.67 -27.17%
2018 $-0.92 283.33%
2017 $-0.24 579.89%
2016 $-0.04 -63.94%
2015 $-0.10 -115.06%
2014 $0.65 32.65%
2013 $0.49 -40.96%
2012 $0.83 38.33%
2011 $0.60 -1,980.88%
2010 $-0.03 -129.00%
2009 $0.11 -150.00%
2008 $-0.22 -166.67%
2007 $0.33 449.08%
2006 $0.06 -86.93%
2005 $0.46 -200.00%
2004 $-0.46 -406.67%
2003 $0.15 15.38%
2002 $0.13 -27.78%
2001 $0.18 -14.29%
2000 $0.21 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$6.03 -2,840.86%
DE
$6.01 -2,830.82%
DE
$1.53 -796.77%
JP
$3.66 -1,763.64%
CH
$0.45 -304.55%
IL

Questions about HLS Therapeutics Inc.'s earnings per share (EPS)

What is HLS Therapeutics Inc.'s earnings per share (EPS)?

HLS Therapeutics Inc.'s earnings per share (EPS) over the last twelve months is $-0.22, as of Sep 2026.

What was HLS Therapeutics Inc.'s earnings per share (EPS) in 2025?

In 2025, HLS Therapeutics Inc.'s earnings per share (EPS) was $-0.40, compared with $-0.62 in 2024.

How has HLS Therapeutics Inc.'s earnings per share (EPS) changed since 2020?

From 2020 to 2025, HLS Therapeutics Inc.'s earnings per share (EPS) was highest in 2025 ($-0.40) and lowest in 2023 ($-0.85).

How does HLS Therapeutics Inc.'s earnings per share (EPS) compare with similar companies?

HLS Therapeutics Inc.'s earnings per share (EPS) ($-0.22) is lower than that of all 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with $6.03.